

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6414846

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
QIAGEN CANADA INC.	12/13/2019
QIAGEN INC.	12/13/2019
RECEIVING PARTY DATA	
Name:	MOLECULAR DIMENSIONS, INC.
Street Address:	434 WEST DUSSEL DRIVE
City:	MAUMEE
State/Country:	OHIO
Postal Code:	43537
PROPERTY NUMBERS Total: 3	
Property Type	Number
Patent Number:	7514043
Patent Number:	7993416
Patent Number:	7316805
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	siepmann@siepmannip.com
Correspondent Name:	SIEPMANN IP, PLLC
Address Line 1:	8837 EAGLE ROCK LANE
Address Line 4:	SPRINGFIELD, VIRGINIA 22153
ATTORNEY DOCKET NUMBER:	4000-0020X
NAME OF SUBMITTER:	HASTINGS GALLOWAY
SIGNATURE:	/Hastings Galloway/
DATE SIGNED:	11/23/2020
Total Attachments: 4	
source=2020-11-23_Assignment_Molecular-Dimensions#page1.tif	
source=2020-11-23_Assignment_Molecular-Dimensions#page2.tif	
source=2020-11-23_Assignment_Molecular-Dimensions#page3.tif	
source=2020-11-23_Assignment_Molecular-Dimensions#page4.tif	

ASSIGNMENT

WHEREAS, QIAGEN Canada Inc., a corporation having a place of business at 1117 Rue Sainte-Catherine Ouest, Montreal, Quebec, Canada H3B 1H9 and **Qiagen Inc.**, a corporation having a place of business at BCE Place, Suite 4400, Bay Wellington Tower, 181 Bay Street, Toronto, Canada M5J 2T3, hereinafter generally referred to as “**ASSIGNORS**”, are the sole and exclusive owners, individually or collectively, of the patents and patent applications listed in the attached Schedule A (“**Inventions**”).

WHEREAS, Molecular Dimensions, Inc., a Florida corporation having a place of business at 434 West Dussel Drive, Maumee, OH 43537, United States, hereinafter generally referred to as “**ASSIGNEE**,” is desirous of memorializing and confirming, or if necessary acquiring, legal and equitable title in the Inventions.

To the extent ASSIGNORS retained any right, title, or interest in or to the Inventions, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound hereby, ASSIGNORS have assigned and/or hereby sell, assign, transfer and convey unto ASSIGNEE, the whole and entire right, title and interest in and to:

all Inventions;

the patents and patent applications as identified in the attached Schedule A, and any and all United States and foreign patent applications disclosing one or more of the Inventions including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, utility models, PCT applications and designs and any other related United States and foreign applications and equivalents thereof (“**Applications**”), along with the right to claim priority to the Applications under any treaty relating thereto;

all United States and foreign patents, utility models, inventor’s certificates and designs and all equivalents thereof which may be granted for the Inventions or Applications, and all post-grant actions including extensions, renewals, reissues, reexamination certificates, post-grant review certificates, inter partes review certificates, and supplemental examination certificates thereof (“**Patents**”); and

all rights to sue for and recover for, and the right to profits and damages due or accrued arising out of or in connection with any and all past, present or future infringements in the United States and all foreign countries, of the Inventions, Applications or Patents for the sole use and benefit of ASSIGNEE, its successors, assigns and legal representatives.

The Inventions, Applications and Patents to be held and enjoyed by ASSIGNEE, for ASSIGNEE’s own use and benefit, and for ASSIGNEE’s legal representatives and assigns to the full end of the term or terms of said granted or to be granted Patents, as fully and entirely as the same would have been held by ASSIGNORS had this assignment not been made; and for the aforesaid consideration ASSIGNORS hereby covenant, agree and undertake to execute, whenever requested by the above-named ASSIGNEE, all patent applications, assignments, declarations, lawful oaths and any other papers which ASSIGNEE may deem necessary or

desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Applications and Patents hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNORS.

It is agreed that ASSIGNORS shall be legally bound, upon request and at the expense of ASSIGNEE or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Inventions, and to testify in any legal proceeding relating thereto.

Each ASSIGNOR hereby represents and warrants that they have full right, power and authority to assign their entire right, title, and interest in the Inventions, Applications, and Patents, and no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.

This Assignment has been duly executed and delivered and constitutes a valid, binding and enforceable assignment of the entire right, title, and interest in the Inventions, Applications, and Patents.


December 13, 2019
Date




QIAGEN Canada Inc.
[ASSIGNOR]

Roland Sackers, CFO

December 13, 2019
Date



QIAGEN Inc.
[ASSIGNOR]


QIAGEN Legal

Roland Sackers, CFO

December 13, 2019
Date

Molecular Dimensions, Inc.
[ASSIGNEE]

NAME, TITLE

desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Applications and Patents hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNORS.

It is agreed that ASSIGNORS shall be legally bound, upon request and at the expense of ASSIGNEE or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Inventions, and to testify in any legal proceeding relating thereto.

Each ASSIGNOR hereby represents and warrants that they have full right, power and authority to assign their entire right, title, and interest in the Inventions, Applications, and Patents, and no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.

This Assignment has been duly executed and delivered and constitutes a valid, binding and enforceable assignment of the entire right, title, and interest in the Inventions, Applications, and Patents.

December 13, 2019

Date

QIAGEN Canada Inc.
[ASSIGNOR]

NAME, TITLE

December 13, 2019


Date

QIAGEN Inc.
[ASSIGNOR]


NAME, TITLE

December 13, 2019

Date



Molecular Dimensions, Inc.
[ASSIGNEE]



NAME, TITLE

SCHEDULE A

Country	Application No.	Filing Date	Issue Date	Patent No.
Australia	AU25291/00	9-Feb-00	9-Sep-04	AU773384
Australia	AU2004205437	16-Jan-04	1-Oct-09	AU2004205437
Austria	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
Belgium	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
Canada	CA2,261,326	9-Feb-99	22-Jan-08	CA 2,261,326
Canada	CA2,360,315	9-Feb-00	22-Jan-08	CA2,360,315
Canada	CA2,513,177	16-Jan-04	20-Mar-12	CA2,513,177
China	CN200480002410.4	16-Jan-04	7-Jan-09	CNZL200480002410.4
Denmark	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
EPO	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
EPO	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
France	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
France	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
GB	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
GB	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
Germany	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
Germany	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
Israel	IL144752	9-Feb-00	21-Jun-05	IL144752
Italy	EP00903455.4	9-Feb-00	12-May-04	IT502004901231569
Italy	EP04702616.6	16-Jan-04	30-Jan-08	IT502008901616854
Japan	JP2000-598269	9-Feb-00	3-Jun-11	JP4753107
Japan	JP2006-0500438	16-Jan-04	16-Nov-06	JP2006-0500438
Mexico	MX/a/2005/007619	16-Jan-04	12-Nov-08	MX262144
Netherlands	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
Netherlands	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
Spain	ES2300738		16-Jun-08	ES2300738
Spain	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
Sweden	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
Switzerland	EP00903455.4	9-Feb-00	12-May-04	EP1148946 B1
Switzerland	EP04702616.6	16-Jan-04	30-Jan-08	EP1699538
United States	US60/440,635	17-Jan-03	N/A	N/A
United States	US60/466,074	29-Apr-03	N/A	N/A
United States	US60/485,400	9-Jul-03	N/A	N/A
World Intellectual Property Organization	PCT/CA00/00119	9-Feb-00	N/A	N/A
World Intellectual Property Organization	PCT/CA2004/00070	16-Jan-04	N/A	N/A